Atopic Dermatitis
Conditions
Interventions
Sponsors
Nemoto Takanori
Torii Pharmaceutical Co.,LTD
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese patients aged >= 12 years at informed consent who can visit the study site as an outpatient 2. Patients with clinical diagnosis of AD according to the criteria of the Japanese Dermatological Association prior to or at informed consent 3. Patients whose IGA score, EASI score, and %BSA affected meet the criteria specified in the study protocol
Exclusion criteria
Exclusion criteria: 1. Patients with a history of or current significant dermatologic or inflammatory condition that, in the investigator's opinion, would make it difficult to interpret data or assessments during the study 2. Patients with a history of or current acute active bacterial, fungal, or viral (e.g., herpes simplex, herpes zoster, and varicella) skin infection within 1 week prior to Week 0 3. Patients who have used any prohibited therapy specified in the study protocol within the indicated period before Week 0 4. Patients with serious concomitant disease(s) 5. Patients with a history of or current cancer within 5 years prior to screening visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events and adverse drug reactions Change from Baseline and clinically significant abnormalities in laboratory test results Change from Baseline and clinically significant abnormalities in vital signs | — |
Contacts
Public Contactclinical trials information
Shionogi & Co.,Ltd.
Outcome results
None listed